Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed ...
"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...
Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
News-Medical.Net on MSN
Largest trial of adjuvant pembrolizumab in Merkel cell carcinoma reports key benefit
A new cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) shows that a drug that utilizes the body's ...
IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in ...
"ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory" was originally created and published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback